Of 124 indications of cancer medicines authorised in the EU from 2011 to 2020, Hungary reimbursed 40%, and the median wait from authorisation to reimbursement was 37 months, the longest of the four countries studied.
The authors followed 124 indications of 51 cancer medicines authorised by the European Medicines Agency in 2011 to 2020 until 2022, and compared reimbursement status and waiting time in Czechia, Hungary, Poland and Slovakia against each indication's ESMO Magnitude of Clinical Benefit Scale rating.
Hungarian patients waited a median of just over three years for new cancer medicines to be reimbursed, and the wait was no shorter for the medicines that help most.
Shares National Health Insurance Fund of Hungary (Nemzeti Egészségbiztosítási Alapkezelő), Lung cancer (all types).
Shares National Health Insurance Fund of Hungary (Nemzeti Egészségbiztosítási Alapkezelő), Lung cancer (all types), Breast cancer (all types).
Shares National Health Insurance Fund of Hungary (Nemzeti Egészségbiztosítási Alapkezelő), Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/